326 related articles for article (PubMed ID: 20878125)
1. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Fukushima M; Sakamoto K; Sakata M; Nakagawa F; Saito H; Sakata Y
Oncol Rep; 2010 Nov; 24(5):1307-13. PubMed ID: 20878125
[TBL] [Abstract][Full Text] [Related]
2. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
4. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Nakaya T; Yonezawa H; Oyama K; Takahashi M; Saito K; Takechi T; Fukushima M; Shirasaka T
Eur J Cancer; 2003 Nov; 39(16):2387-94. PubMed ID: 14556932
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
6. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
[TBL] [Abstract][Full Text] [Related]
7. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.
Fukushima M; Satake H; Uchida J; Shimamoto Y; Kato T; Takechi T; Okabe H; Fujioka A; Nakano K; Ohshimo H; Takeda S; Shirasaka T
Int J Oncol; 1998 Oct; 13(4):693-8. PubMed ID: 9735397
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
Nukatsuka M; Saito H; Sakamoto K; Nakagawa F; Uchida J; Kobunai T; Shiraishi K; Takechi T
Anticancer Res; 2012 Jul; 32(7):2807-12. PubMed ID: 22753741
[TBL] [Abstract][Full Text] [Related]
9. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T
Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729
[TBL] [Abstract][Full Text] [Related]
10. Pre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced its Anti-tumor Effect for Colorectal Cancer.
Baba T; Kokuryo T; Yamaguchi J; Yokoyama Y; Uehara K; Ebata T; Nagino M
Anticancer Res; 2018 Mar; 38(3):1427-1434. PubMed ID: 29491068
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of combination chemotherapy with UFT and cyclophosphamide against human breast cancer xenografts in nude mice.
Haga S; Shimizu T; Imamura H; Watanabe O; Kinoshita J; Fukushima M; Kajiwara T
Anticancer Res; 1999; 19(3A):1791-6. PubMed ID: 10470117
[TBL] [Abstract][Full Text] [Related]
12. The role of additional chemotherapy with oral UFT in intravenous combination chemotherapy with cisplatin and 5-fluorouracil for human gastric cancer xenograft lines of well- and poorly- differentiated adenocarcinomas transplanted in nude mice.
Tseng CC; Nio Y; Tsubono M; Kawabata K; Masai Y; Hayashi H; Fukumoto M; Tobe T
Anticancer Res; 1992; 12(4):1295-9. PubMed ID: 1503424
[TBL] [Abstract][Full Text] [Related]
13. Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells.
Cui J; Wang MC; Zhang YM; Ren MZ; Wang SX; Nan KJ; Song LP
Cancer Chemother Pharmacol; 2018 Apr; 81(4):717-726. PubMed ID: 29480364
[TBL] [Abstract][Full Text] [Related]
14. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
15. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Schöffski P
Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
[TBL] [Abstract][Full Text] [Related]
16. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
Hoff PM
Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism.
Cai JP; Chen W; Hou X; Liang LJ; Hao XY; Yin XY
Anticancer Drugs; 2013 Nov; 24(10):1020-9. PubMed ID: 23941814
[TBL] [Abstract][Full Text] [Related]
18. S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Nakata E; Fukushima M; Takai Y; Nemoto K; Ogawa Y; Nomiya T; Nakamura Y; Milas L; Yamada S
Oncol Rep; 2006 Sep; 16(3):465-71. PubMed ID: 16865244
[TBL] [Abstract][Full Text] [Related]
19. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Mori T; Fujiwara Y; Yano M; Tamura S; Yasuda T; Takiguchi S; Monden M
Oncology; 2003; 64(2):176-82. PubMed ID: 12566916
[TBL] [Abstract][Full Text] [Related]
20. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
Tsujie M; Nakamori S; Nakahira S; Takeda S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Pancreas; 2006 Aug; 33(2):142-7. PubMed ID: 16868479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
